Related Experiment Video
Updated: Jun 2, 2026

Spontaneous Murine Model of Anaplastic Thyroid Cancer
Published on: February 3, 2023
Multiple endocrine neoplasia type 2: an overview
1Genomic Medicine Institute, Lerner Research Institute, Cleveland Clinic, Cleveland, Ohio, USA.
Abstract:
Multiple endocrine neoplasia type 2 is historically composed of three clinical subtypes, all of which are associated with germline mutations in the RET proto-oncogene. Multiple endocrine neoplasia type 2A, familial medullary thyroid carcinoma, and multiple endocrine neoplasia type 2B are collectively associated with a 70-100% risk of medullary thyroid carcinoma by age 70 years. Pheochromocytomas are identified in 50% of individuals with multiple endocrine neoplasia type 2A and multiple endocrine neoplasia type 2B. Furthermore, those with multiple endocrine neoplasia type 2A have a 20-30% risk for primary hyperparathyroidism. Individuals with multiple endocrine neoplasia type 2B often have distinct physical features including mucosal neuromas of the lips and tongue, medullated corneal nerve fibers, ganglioneuromatosis of the gastrointestinal tract, distinctive facies with enlarged lips, and a "Marfanoid" body habitus. Clinical recognition and accurate diagnosis of individuals and families who are at risk of harboring a germline RET mutation is critical for the prevention and management of potentially life-threatening neoplasms. This overview summarizes the clinical description of multiple endocrine neoplasia type 2, diagnosis and testing strategies, management and surveillance, and differential diagnosis for other related syndromes.
Insights
Multiple endocrine neoplasia type 2 (MEN2) involves RET gene mutations, leading to high risks of medullary thyroid carcinoma and other tumors. Early diagnosis and management are crucial for preventing life-threatening conditions.
Area of Science:
- Endocrinology
- Genetics
- Oncology
Background:
- Multiple endocrine neoplasia type 2 (MEN2) comprises three subtypes linked to germline RET proto-oncogene mutations.
- MEN2 subtypes carry a significant risk of medullary thyroid carcinoma (MTC), pheochromocytomas, and primary hyperparathyroidism.
Purpose of the Study:
- To provide a comprehensive overview of MEN2, including clinical presentations, diagnostic strategies, and management guidelines.
- To emphasize the critical role of early clinical recognition and genetic testing for RET mutations in managing MEN2-associated neoplasms.
Main Methods:
- Review of clinical descriptions of MEN2 subtypes.
- Summary of diagnostic and testing strategies for germline RET mutations.
- Outline of management, surveillance, and differential diagnosis for MEN2.
Main Results:
- MEN2 subtypes share a high lifetime risk for MTC (70-100%) and pheochromocytomas (50%).
- MEN2A has a 20-30% risk of primary hyperparathyroidism; MEN2B presents with distinct physical features and gastrointestinal issues.
- Germline RET mutations are the underlying cause across all MEN2 subtypes.
Conclusions:
- Clinical recognition of MEN2 subtypes and timely RET mutation testing are essential for effective prevention and management.
- Proactive surveillance and management strategies are critical for individuals and families at risk of MEN2-related neoplasms.
Related Concept Videos
Type II Diabetes II: Pathophysiology
Type II Diabetes I: Introduction
Hyperthyroidism II: Pathophysiology
Type I Diabetes II: Pathophysiology
Cushing Syndrome II: Pathophysiology
Cancer-Critical Genes II: Tumor Suppressor Genes
When the function of certain critical genes, especially those involved in cell cycle regulation and cell growth signaling cascades, gets disrupted, it upsets the cell cycle progression. Such cells with unchecked cell cycles start proliferating uncontrollably and eventually develop into tumors.
Such genes that act...